Mounting evidence supports a toxic gain-of-function role of APOE4 in AD pathogenesis, with studies in preclinical models consistently demonstrating that reducing APOE4 levels alleviates multiple pathological features, including amyloid and tau pathology, neurodegeneration, and neuroinflammation. This evidence concerns the gene APOE and Alzheimer disease.